Anti-C1q autoantibodies do not correlate with the occurrence or severity of experimental lupus nephritis

Bigler, Cornelia; Hopfer, Helmut; Danner, Doris; Mihatsch, Michael J.; Trendelenburg, Marten

doi:10.1016/j.molimm.2010.05.041

Cited by 6 publications

(7 citation statements)

References 18 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although a clinical signi cance has been observed between the existence of anti-C1q antibodies and LN, the diagnostic value and pathogenic role of antibodies to C1q in LN remains controversial [21,29]. Anti-C1q autoantibodies may be found in the sera of healthy individuals and patients with other autoimmune diseases such as rheumatoid vasculitis, mixed connective tissue disease (MCTD), Felty syndrome (FS), and autoimmune thyroid disease [22,30,31].…”

Section: Discussionmentioning

confidence: 99%

The Concurrent Anti-C1q and Anti-dsDNA but not Anti-C3b Antibodies as Potent Biomarkers for Lupus Nephritis prediction

Kianmehr¹,

Khoshmirsafa²,

Shekarabi³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Lupus Nephritis (LN) in patients with Systemic Lupus Erythematosus (SLE) is one of the most serious and prevalent manifestations. The procedure of renal biopsy is harmful and accompanied by potential hazards. Therefore, introducing reliable biomarkers to predict LN is exceedingly worthwhile. In the current study, we compared the diagnostic values of circulating autoantibodies against dsDNA, C1q, C3b, SSA, SSB, and Sm alone or in combination to predict LN.Methods: This study evaluated abovementioned autoantibodies in 40 healthy controls (HCs) and 95 SLE patients with different kidney involvements, including absent (n = 40), inactive (n = 20), and active (n= 35) LN using EIA method.Result: The frequency and odds ratio of anti-dsDNA (71.4%, OR=4.2), anti-C1q (62.9%, OR= 5.1), and the simultaneous existence of anti-C1q and anti-dsDNA (51.4%, OR=6) antibodies were significantly higher in the active LN group compared with both inactive and absent LN groups. Moreover, the levels of anti-C1q and anti-dsDNA antibodies positively correlated with disease activity in patients with SLE. The prevalence of these autoantibodies was associated with the severity of LN biopsies. Conclusion: These data suggest that anti-C1q and anti-dsDNA antibodies and also the simultaneous presence of them may be valuable diagnostic biomarkers for LN prediction in patients with SLE.

show abstract

Section: Discussionmentioning

confidence: 99%

The Concurrent Anti-C1q and Anti-dsDNA but not Anti-C3b Antibodies as Potent Biomarkers for Lupus Nephritis prediction

Kianmehr¹,

Khoshmirsafa²,

Shekarabi³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Anti-dsDNA antibodies have been widely used as a clinical biomarker of LGLN occurrence or relapse [17,18]. Furthermore, anti-C1q antibodies have recently emerged as perpetuators of renal inflammation [19][20][21][22], yet their pathogenetic potential is currently being challenged [23][24][25]. Unfortunately, no reliable biomarkers able to predict LGLN in SLE patients have been identified to date [26].…”

Section: Discussionmentioning

confidence: 99%

PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis

Bassi

Prete

Ghirardello

et al. 2015

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Pentraxin 3 (PTX3) is an acute-phase protein involved in C1q clearance. The presence of anti-C1q and the absence of anti-PTX3 antibodies were associated with lupus glomerulonephritis (LGLN). Our aim was to assess soluble and kidney-expressed PTX3 and their relationships with anti-C1q and anti-PTX3 antibodies in LGLN. Serum PTX3, anti-C1q, anti-dsDNA, and anti-PTX3 antibodies were tested in 130 systemic lupus erythematosus (SLE) patients, 130 healthy and 127 disease controls. Twenty-nine renal biopsies from SLE patients were analyzed and PTX3 immunostaining was quantified by morphometric analysis. Parametric and nonparametric statistics were performed. PTX3 serum levels were lower in SLE versus controls, but they were correlated with proteinuria in LGLN patients (p = 0.001). LGLN patients had higher anti-C1q and lower anti-PTX3 antibody levels than those without (p < 0.0001). LGLN was more prevalent in anti-C1q(+)/anti-PTX3(-) than in anti-C1q(+)/anti-PTX3(+) patients (p < 0.001). No LGLN was observed in anti-C1q(-)/anti-PTX3(+) patients. PTX3 was expressed in glomeruli and renal interstitium. Renal PTX3 was correlated with proteinuria (p = 0.024) and interstitial fibrosis (p = 0.023). PTX3 staining and fibrosis were higher in anti-PTX3(-) than anti-PTX3(+) patients. In conclusion, PTX3 is expressed in glomeruli of LGLN patients, primarily in anti-PTX3(-) patients, where it is correlated with renal fibrosis. Anti-C1q/anti-PTX3 antibody profile seems to be useful in LGLN assessment.

show abstract

“…In this context, the binding of anti-C1q to C1q might interfere with biological functions of C1q beyond complement activation, e.g., the clearance of apoptotic cell material. As has been shown previously, C1q bound to the surface of apoptotic cells is targeted by anti-C1q [9], which thereby decreases phagocytosis of apoptotic cells by THP-1 cells [15]. Whether anti-C1q bound to C1q on apoptotic cells also amplify complement activation and as a consequence alter the interaction with immune cells, needs to be further studied.…”

Section: Discussionmentioning

confidence: 85%

“…A rational reason for low C1q levels are autoantibodies against C1q (anti-C1q) that are present in 20-50% of unselected SLE patients. Anti-C1q levels in these patients not only correlate with hypocomplementemia but also with the occurrence of proliferative lupus nephritis [9][10][11]. Limited evidence is available supporting a direct role of these autoantibodies in the pathogenesis of lupus nephritis.…”

Section: Introductionmentioning

confidence: 91%

Anti-C1q autoantibodies from systemic lupus erythematosus patients activate the complement system via both the classical and lectin pathways

Thanei

Vanhecke

Trendelenburg

2015

Clinical Immunology

Self Cite

View full text Add to dashboard Cite

Anti-C1q autoantibodies do not correlate with the occurrence or severity of experimental lupus nephritis

Cited by 6 publications

References 18 publications

The Concurrent Anti-C1q and Anti-dsDNA but not Anti-C3b Antibodies as Potent Biomarkers for Lupus Nephritis prediction

The Concurrent Anti-C1q and Anti-dsDNA but not Anti-C3b Antibodies as Potent Biomarkers for Lupus Nephritis prediction

PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis

Anti-C1q autoantibodies from systemic lupus erythematosus patients activate the complement system via both the classical and lectin pathways

Contact Info

Product

Resources

About